Catalent Inc Expected to Post Q4 2019 Earnings of $0.65 Per Share (CTLT)
Catalent Inc (NYSE:CTLT) – Analysts at First Analysis issued their Q4 2019 earnings estimates for Catalent in a research note issued to investors on Thursday, August 30th. First Analysis analyst forecasts that the company will post earnings of $0.65 per share for the quarter.
Several other brokerages have also recently issued reports on CTLT. Zacks Investment Research raised Catalent from a “hold” rating to a “buy” rating and set a $44.00 target price on the stock in a report on Thursday, May 10th. ValuEngine lowered shares of Catalent from a “buy” rating to a “hold” rating in a research note on Tuesday, June 5th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Catalent from $50.00 to $55.00 and gave the stock an “overweight” rating in a research note on Wednesday. Five research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $48.09.
Catalent (NYSE:CTLT) last issued its quarterly earnings results on Tuesday, August 28th. The company reported $0.67 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.61 by $0.06. The business had revenue of $685.30 million for the quarter, compared to the consensus estimate of $690.69 million. Catalent had a net margin of 3.39% and a return on equity of 20.42%. The firm’s quarterly revenue was up 11.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.65 EPS.
A number of hedge funds and other institutional investors have recently bought and sold shares of CTLT. Nelson Van Denburg & Campbell Wealth Management Group LLC acquired a new stake in shares of Catalent in the 2nd quarter worth about $145,000. Moneta Group Investment Advisors LLC increased its holdings in shares of Catalent by 105.0% in the 2nd quarter. Moneta Group Investment Advisors LLC now owns 3,515 shares of the company’s stock worth $147,000 after acquiring an additional 1,800 shares during the period. Point72 Asia Hong Kong Ltd increased its holdings in shares of Catalent by 35,700.0% in the 1st quarter. Point72 Asia Hong Kong Ltd now owns 3,938 shares of the company’s stock worth $162,000 after acquiring an additional 3,927 shares during the period. Hartford Investment Management Co. acquired a new stake in shares of Catalent in the 2nd quarter worth about $220,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Catalent in the 1st quarter worth about $229,000. Hedge funds and other institutional investors own 98.76% of the company’s stock.
In other Catalent news, SVP Steven L. Fasman sold 2,252 shares of the stock in a transaction on Wednesday, June 20th. The shares were sold at an average price of $41.78, for a total transaction of $94,088.56. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.70% of the company’s stock.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.
Featured Story: How Do You Calculate Return on Investment (ROI)?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.